Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ANAC > SEC Filings for ANAC > Form 8-K on 30-Nov-2012All Recent SEC Filings

Show all filings for ANACOR PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro



Other Events


On November 28, 2012, Anacor Pharmaceuticals, Inc. (Anacor) announced the completion of two Phase 1 safety studies of tavaborole for onychomycosis - a thorough QT (TQT), or cardiac safety, study and a Repeat Insult Patch Test (RIPT), which assessed skin sensitizing potential and cumulative irritation potential after repeated applications on skin. The announcement was made by Anacor's Chief Executive Officer, David P. Perry, at the Piper Jaffray Healthcare Conference in New York, New York. Tavaborole met the primary objectives in both of these safety studies.

The primary objective of the TQT trial was to assess the electrocardiogram (ECG) effects of tavaborole following multiple-dose administration of tavaborole 5% solution relative to vehicle in healthy adult male and female subjects. Preliminary results from this study demonstrate that tavaborole is safe and has no effect on heart rate, PR and QRS interval duration, cardiac morphology, or cardiac repolarization.

The primary objectives of the RIPT study were to determine the potential of tavaborole to induce sensitization or to cause irritation by repeated topical application to healthy skin. Preliminary results from the RIPT study indicate that tavaborole is not a skin sensitizing agent.

  Add ANAC to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ANAC - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.